| Trial ID: | L0235 |
| Source ID: | NCT00308971
|
| Associated Drug: |
Alpha, Gamma, Beta, And Delta (Mixed) Tocopherols
|
| Title: |
Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Alpha, gamma, beta, and delta (mixed) tocopherols|DRUG: alpha lipoic acid|DRUG: placebo|DRUG: placebo
|
| Outcome Measures: |
Primary: A statistically significant decrease in F2-isoprostanes, a specific oxidative stress marker, 4 months | Secondary: A significant change in biomarkers of acute inflammation and oxidative stress from serum, 4 months|A significant change in brachial artery vasodilatation measured by brachial impedence plethysmography, 4 months
|
| Sponsor/Collaborators: |
Sponsor: Vanderbilt University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
62
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-03
|
| Completion Date: |
2007-07
|
| Results First Posted: |
|
| Last Update Posted: |
2009-07-09
|
| Locations: |
Maine Medical Center, Portland, Maine, 04102, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00308971
|
